# Medpace Holdings, Inc. – Consensus ‘buy’ rating and 8.8% Upside Potential

- Link: https://www.directorstalkinterviews.com/medpace-holdings-inc.consensus-buy-rating-and-8.8-upside-potential/4121129764
- Published: 2023-10-13T14:11:04+01:00
- Author: Charlotte Edwards

**Medpace Holdings, Inc.** which can be found using ticker (MEDP) now have 4 market
analysts covering the stock. The analyst consensus now points to a rating of ‘buy’.
The target price High/Low ranges between 273 and 260 with the average target price
sitting at $267.00. Given that the stocks previous close was at $245.43 this indicates
there is a potential upside of 8.8%. The 50 day MA is $257.78 while the 200 day 
moving average is $224.26. The market cap for the company is 7.28B. The stock price
for the company is currently 238.06 USD

 The potential market cap would be $7,915,223,427 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 29.57, revenue per share of 54.09
and a 14.64% return on assets.

Medpace Holdings, Inc. is a global provider of clinical research-based drug and 
medical device development services. The Company is focused on providing scientifically
driven outsourced clinical development services to the biotechnology, pharmaceutical
and medical device industries. The Company partners with pharmaceutical, biotechnology,
and medical device companies in the development and execution of clinical trials.
The Company’s drug development services focuses on full-service Phase I-IV clinical
development services and include development plan design, coordinated central laboratory,
project management, regulatory affairs, clinical monitoring, data management and
analysis, pharmacovigilance new drug application submissions, and post-marketing
clinical support. It also provides bio-analytical laboratory services, clinical 
human pharmacology, imaging services, and electrocardiography reading support for
clinical trials. Its operations are based in North America, Europe, and Asia.

Share on: